Global Mild Traumatic Brain Injury Overview
Mild Traumatic Brain Injury also called as concussion where an injury to the brain caused from externally inflicted trauma which causes damage to the blood vessels and brain cells. The symptoms includes, any loss of memory for events before or after an accident, loos of consciousness, and others.
Global Mild Traumatic Brain Injury Drivers & Restraints
Drivers |
Restrains |
Rising number of road accidents across globe |
High costs |
Growing geriatric population |
|
Increased number of clinical trials worldwide in order to develop effective therapies for TBI |
|
New launched product and increased product approval |
|
Global Mild Traumatic Brain Injury Segmentations & Regional Insights
The target market is segmented based on Device Type, Technique, End-Users, and Region.
Device Type Insight
On the basis of Device Type, the target market is segmented into Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices.
Technique Insight
On the basis of Technique, the target market is segmented into Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2).
End-Users Insight
On the basis of End-Users, the target market is segmented into Hospitals, Diagnostic Imaging Centers, and Others.
Regional Insights:
On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America market is estimated to witness a significantly high revenue share over the forecast period.
- Rising prevalence of traumatic brain injury diseases.
- Continuous technological development.
- Presence of major players.
- Increased number of product approvals.
- Well-developed healthcare infrastructure.
Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.
- Rising awareness among patients regarding mild traumatic brain injury treatment.
- Improved healthcare infrastructure.
- Growing number of players operating in medical industry to develop lower costs and improve mild traumatic brain injury treatment reliability in expanding markets such as India and China.
Recent Development:
The New Launched Product News,
- In March 2023, Abbott received U.S. FDA (Food and Drug Administration) clearance for its first commercially available lab-based blood test to detect concussion also called as mild traumatic brain injury (TBI). The test “i-STAT TBI” which runs on Abbott’s Alinity i laboratory instrument provides clinicians to quickly access individuals with mild TBIs. The test is widely available in hospitals at United States.
Report Scope:
Attribute |
Details |
Base year for estimation |
2022 |
Forecast period |
2022 – 2032 |
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
Market Segmentation |
By Device Type - Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices By Technique - Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2). By End-Users - Hospitals, Diagnostic Imaging Centers, and Others |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.
Few Other Promising Reports:
Global Mild Traumatic Brain Injury Competitive Landscape & Key Players
The key players operating the target market includes, TEVA Pharmaceutical Industries Ltd., Neuren Pharmaceuticals Ltd., Medtronic plc., NeuroScience Pharmaceuticals, Tenax Therapeutics, Inc., Vasopharm GmbH, Amarantus Bio Science Holdings Inc., Silver Creek Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Banayan Biomarkers, Inc.
Global Mild Traumatic Brain Injury Highlights
FAQs
The growing adoption of innovative technology and new areas of research will potentially change the TBI management that includes, treatment techniques, biomarkers and medications which in turn, is expected to fruitful the demand for target market growth.
By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.
The key players operating the target market includes, TEVA Pharmaceutical Industries Ltd., Neuren Pharmaceuticals Ltd., Medtronic plc., NeuroScience Pharmaceuticals, Tenax Therapeutics, Inc., Vasopharm GmbH, Amarantus Bio Science Holdings Inc., Silver Creek Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Banayan Biomarkers, Inc.